Navigation Links
Sosei Announces Outcome of Strategy Review
Date:5/13/2008

TOKYO, May 14 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces the outcome of its strategy review.

In view of the current market conditions, the difficulty in raising finance at the current low share price, and the problems associated with the AD923 device which has necessitated a halt to the Phase III trials Sosei has taken decisive action to cut costs, streamline its operation and to secure the future of the business until it becomes a significant income generating business from NVA237/QVA149 in a few years time.

- Sosei is closing its Chesterford operation and Sosei R&D's

continuing business will relocate to London in due course. This will

reduce UK headcount by c 40 staff and provide a full years cost saving of

around $4M.

- Sosei will no longer operate a drug discovery unit.

- Sosei R&D will maintain the rights to NVA237/QVA149 but seek

to out-license or sell all other assets generated in the UK including

AD923 and its discovery assets whilst seeking to retain some rights for

the Asian market.

- Tokyo will continue to develop Norlevo and explore other

in-licensing opportunities.

This restructuring and portfolio review will provide Sosei with at least two years cash based on the post-restructuring cash burn including a budget allocation to explore some late stage product opportunities for future expansion but without the inclusion of any income from licensing or sales deals for its compounds.

Notes for Editors:

About Sosei

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical mark
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
2. BD Announces Acquisition of Cytopeia
3. Chindex International Announces Shelf Registration, Related Strategy and Guidance
4. Amicus Therapeutics Announces First Quarter 2008 Financial Results
5. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008
6. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
7. China Sky One Medical, Inc. Announces Record First Quarter 2008 Results
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
11. Aton Pharma Announces Distribution Partnership in Brazil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 /PRNewswire/ ... has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. ... the pharmaceutical and biotechnology industries is anticipated. ... of drug development - from formulations for ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... treated and managed with the use of special anti-vascular endothelial growth factor agents ... many more patients, currently does not have a scientific protocol for the many ...
(Date:9/2/2015)... Biovista Inc. is glad to ... BeHEARD science challenge, a global competition hosted by the ... to the latest life science innovations and technologies. ... analytics capability to support Steven Laffoon and ... of Niemann-Pick Disease Type A (NPA), a rare and ...
(Date:9/2/2015)... Colo. , Sept. 2, 2015 Aytu ... on developing treatments for urological and related conditions, announced ... its planned private placement convertible note financing, raising a ... prior tranches totaling $3.175 million. ... "Proceeds from this private placement are intended to be ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
... Q4 2007 net revenues grew 29.8%, as compared to Q4 2006, to RMB45.7 ... million) - Q4 2007 net income grew 152.2%, as compared to Q4 2006, to RMB17.9 ... million (US$2.5 million), - 2007 fiscal year net revenues increased 41.0% year-over-year to RMB180.2 ... (US$24.7 million),- 2007 fiscal year net income grew 167.4% year-over-year to RMB81.5 million ...
... to rust plays a similarly corrosive role in our bodies. ... process, scientists know, that contributes to a host of diseases ... stroke to cancer and the inexorable process of aging. , ... the journal Nature, a team of University of Wisconsin-Madison scientists ...
... & Speciated Analysis Brings Unprecedented ... ... the EPA Method 6800 has been published in,January 2008 edition of the ... of US environmental statutes known as RCRA (Resource,Conservation and Recovery Act). This ...
Cached Biology Technology:3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 23SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 33SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 43SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 53SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 63SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 73SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 83SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 93SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 103SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 113SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 123SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 133SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 143SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 153SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 16Genetic pathway critical to disease, aging found 2Genetic pathway critical to disease, aging found 3Newly Published EPA RCRA Method 6800 Supports AIT Technology 2
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) has announced the ... - Growth, Trends & Forecasts (2014-2020)" report to ... Sensors market is estimated at $0.23 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
(Date:8/26/2015)... The report "Multi-Factor Authentication (MFA) Market ... (Travel & Immigration, Government, Banking, Defense, Commercial Security, Consumer ... published by MarketsandMarkets, Multi-Factor Authentication Market is expected to ... CAGR of 17.7% between 2015 and 2020. ... spread through 169 P ages and ...
(Date:8/24/2015)... , August 24, 2015 The ... ,s largest biometrics manufacturer DERMALOG and its customized solutions ... "2015 African Biometrics Company of the Year Award". DERMALOG is ... Nigeria .   -Cross reference: Picture is ... - On Thursday evening, in ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... MASS. In a study that analyzed relationships ... University researcher has developed a new statistical model ... time periods where such information is not available. ... urban and environmental policy and planning at Tufts ...
... marijuana-like compounds called endocannabinoids alter genes and biological signals ... pregnancy and may contribute to pregnancy complications like preeclampsia. ... The Journal of Biological Chemistry offers new ... produced by the body disrupts the movement of early ...
... 2012 Using old deeds and witness trees, a ... the composition of the forests that covered today,s Monongahela ... "European Settlement-Era Vegetation of the Monongahela National Forest, West ... West Virginia University colleague answered questions about the composition ...
Cached Biology News:New model could help fill data gap in predicting historical air pollution exposure 2New model could help fill data gap in predicting historical air pollution exposure 3Study implicates marijuana use in pregnancy problems 2Old deeds, witness trees offer glimpse of pre-settlement forest in West Virginia 2Old deeds, witness trees offer glimpse of pre-settlement forest in West Virginia 3
... DeCypher combines enterprise-scale sequence analysis software with ... bioinformatics analyses. With DeCypher, you can perform searches ... ESTs vs NCBI NT database in under 6 ... to genomic DNA Use HMM analysis ...
...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
...
Biology Products: